If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Humalog® Therapies
Humalog® U-100 (insulin lispro injection)
100 units/mLHumalog® U-200 (insulin lispro injection)
200 units/mLHumalog® MIX50/50™ (50% insulin lispro protamine suspension 50% insulin lispro injection [rDNA origin])
100 units/mLHumalog® MIX75/25™ (75% insulin lispro protamine suspension 25% insulin lispro injection [rDNA origin])
100 units/mLThis information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
HUMALOG® (insulin lispro) 200 Units/mL: Administration
Humalog 200 units/mL is available as a 3 mL KwikPen for subcutaneous use.
Administer the dose of IL-200 within 15 minutes before a meal or immediately after a meal by SC injection into the abdominal wall, thigh, upper arm, or buttocks.1
IL-200 is available only as a 3 mL Pen for SC use.1
Do NOT transfer IL-200 from the Pen to a syringe as the markings on the insulin syringe will not measure the dose correctly and can result in overdosage and severe hypoglycemia.1
Do NOT administer IL-200 using a CSII (eg, insulin pump).1
Do NOT administer IL-200 by IV infusion.1
Do NOT mix IL-200 with any other insulins.1
Enclosed Prescribing Information
HUMALOG® (insulin lispro injection), for subcutaneous or intravenous use, Lilly
1. Humalog [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.
Glossary
CSII = continuous subcutaneous insulin infusion
IL-200 = Humalog® (insulin lispro injection) 200 units/mL
IV = intravenous
Pen = KwikPen®
SC = subcutaneous
Date of Last Review: December 13, 2019